Connect MM registry

The importance of establishing baseline disease characteristics

Robert M. Rifkin, Rafat Abonour, Howard Terebelo, Jatin J. Shah, Cristina Gasparetto, James Hardin, Shankar Srinivasan, Rosanna Ricafort, Yasir Nagarwala, Brian G M Durie

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background Connect MM is the first and largest observational, noninterventional, prospective registry of patients newly diagnosed with multiple myeloma (NDMM) in the United States. It collects longitudinal data on patients within clinical practice including patients in clinical trials. Patients and Methods Of the 1513 patients enrolled, 1493 were protocol-eligible. Results Median age was 67 years, 81.9% (1223/1493) were Caucasian, and 57.2% (854/1493) were male. Of these patients, 26.5% (232/877) were International Staging System stage I, 34.9% (306/877) stage II, and 38.7% (339/877) stage III. Eastern Cooperative Oncology Group performance status of 0/1/2 were reported in 96.6% (1017/1053). Clonal plasma cells > 10% were found in 91.6% (1282/1399) of patients and M-component in 98.8% (1343/1359). Hypercalcemia was present in 7.3% (108/1481) of patients, serum creatinine > 2 mg/dL in 18.3% (271/1484), anemia in 45.1% (673/1493), and bone involvement in 76.7% (1143/1490). Of the 15 National Comprehensive Cancer Network (NCCN) recommended diagnostic tests, a median of 12 were performed. Lactate dehydrogenase assessment, serum free light chain ratio, and immunofixation were reported in 38.4% (574/1493), 62.1% (927/1493), and 66% (985/1493) of patients, respectively. Quantitative immunoglobulin, β-2 microglobulin, and protein electrophoresis (serum or urine) were reported in 72.3% (1080/1493), 74.1% (1107/1493), and 78.0% (1164/1493) of patients, respectively. Bone marrow biopsy was reported in 92.2% (1376/1493), but conventional cytogenetic and fluorescence in situ hybridization analysis were reported in only 63.2% (944/1493) and 59.8% (893/1493) of patients, respectively. A high-risk cytogenetic profile (according to International Myeloma Working Group [IMWG] criteria) was found in 16.9% (253/1493). Conclusion This analysis provides insight into the demographic and disease characteristics of NDMM patients in a range of clinical practices. Creating solid records of baseline patient disease characteristics using suggested NCCN diagnostic work-up and IMWG criteria provides a foundation for monitoring disease progression and response to treatment.

Original languageEnglish (US)
Pages (from-to)368-376
Number of pages9
JournalClinical Lymphoma, Myeloma and Leukemia
Volume15
Issue number6
DOIs
StatePublished - Jun 1 2015

Fingerprint

Registries
Multiple Myeloma
Cytogenetics
Myeloma Proteins
Hypercalcemia
Plasma Cells
Serum
Fluorescence In Situ Hybridization
L-Lactate Dehydrogenase
Routine Diagnostic Tests
Disease Progression
Electrophoresis
Immunoglobulins
Anemia
Blood Proteins
Creatinine
Neoplasms
Bone Marrow
Demography
Clinical Trials

Keywords

  • Baseline Disease Characteristics
  • Diagnostics
  • IMWG
  • Multiple Myeloma
  • NCCN Guidelines

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Connect MM registry : The importance of establishing baseline disease characteristics. / Rifkin, Robert M.; Abonour, Rafat; Terebelo, Howard; Shah, Jatin J.; Gasparetto, Cristina; Hardin, James; Srinivasan, Shankar; Ricafort, Rosanna; Nagarwala, Yasir; Durie, Brian G M.

In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 15, No. 6, 01.06.2015, p. 368-376.

Research output: Contribution to journalArticle

Rifkin, RM, Abonour, R, Terebelo, H, Shah, JJ, Gasparetto, C, Hardin, J, Srinivasan, S, Ricafort, R, Nagarwala, Y & Durie, BGM 2015, 'Connect MM registry: The importance of establishing baseline disease characteristics', Clinical Lymphoma, Myeloma and Leukemia, vol. 15, no. 6, pp. 368-376. https://doi.org/10.1016/j.clml.2014.12.002
Rifkin, Robert M. ; Abonour, Rafat ; Terebelo, Howard ; Shah, Jatin J. ; Gasparetto, Cristina ; Hardin, James ; Srinivasan, Shankar ; Ricafort, Rosanna ; Nagarwala, Yasir ; Durie, Brian G M. / Connect MM registry : The importance of establishing baseline disease characteristics. In: Clinical Lymphoma, Myeloma and Leukemia. 2015 ; Vol. 15, No. 6. pp. 368-376.
@article{11b4cecfd08c4fa1afc89980d84838d2,
title = "Connect MM registry: The importance of establishing baseline disease characteristics",
abstract = "Background Connect MM is the first and largest observational, noninterventional, prospective registry of patients newly diagnosed with multiple myeloma (NDMM) in the United States. It collects longitudinal data on patients within clinical practice including patients in clinical trials. Patients and Methods Of the 1513 patients enrolled, 1493 were protocol-eligible. Results Median age was 67 years, 81.9{\%} (1223/1493) were Caucasian, and 57.2{\%} (854/1493) were male. Of these patients, 26.5{\%} (232/877) were International Staging System stage I, 34.9{\%} (306/877) stage II, and 38.7{\%} (339/877) stage III. Eastern Cooperative Oncology Group performance status of 0/1/2 were reported in 96.6{\%} (1017/1053). Clonal plasma cells > 10{\%} were found in 91.6{\%} (1282/1399) of patients and M-component in 98.8{\%} (1343/1359). Hypercalcemia was present in 7.3{\%} (108/1481) of patients, serum creatinine > 2 mg/dL in 18.3{\%} (271/1484), anemia in 45.1{\%} (673/1493), and bone involvement in 76.7{\%} (1143/1490). Of the 15 National Comprehensive Cancer Network (NCCN) recommended diagnostic tests, a median of 12 were performed. Lactate dehydrogenase assessment, serum free light chain ratio, and immunofixation were reported in 38.4{\%} (574/1493), 62.1{\%} (927/1493), and 66{\%} (985/1493) of patients, respectively. Quantitative immunoglobulin, β-2 microglobulin, and protein electrophoresis (serum or urine) were reported in 72.3{\%} (1080/1493), 74.1{\%} (1107/1493), and 78.0{\%} (1164/1493) of patients, respectively. Bone marrow biopsy was reported in 92.2{\%} (1376/1493), but conventional cytogenetic and fluorescence in situ hybridization analysis were reported in only 63.2{\%} (944/1493) and 59.8{\%} (893/1493) of patients, respectively. A high-risk cytogenetic profile (according to International Myeloma Working Group [IMWG] criteria) was found in 16.9{\%} (253/1493). Conclusion This analysis provides insight into the demographic and disease characteristics of NDMM patients in a range of clinical practices. Creating solid records of baseline patient disease characteristics using suggested NCCN diagnostic work-up and IMWG criteria provides a foundation for monitoring disease progression and response to treatment.",
keywords = "Baseline Disease Characteristics, Diagnostics, IMWG, Multiple Myeloma, NCCN Guidelines",
author = "Rifkin, {Robert M.} and Rafat Abonour and Howard Terebelo and Shah, {Jatin J.} and Cristina Gasparetto and James Hardin and Shankar Srinivasan and Rosanna Ricafort and Yasir Nagarwala and Durie, {Brian G M}",
year = "2015",
month = "6",
day = "1",
doi = "10.1016/j.clml.2014.12.002",
language = "English (US)",
volume = "15",
pages = "368--376",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",
number = "6",

}

TY - JOUR

T1 - Connect MM registry

T2 - The importance of establishing baseline disease characteristics

AU - Rifkin, Robert M.

AU - Abonour, Rafat

AU - Terebelo, Howard

AU - Shah, Jatin J.

AU - Gasparetto, Cristina

AU - Hardin, James

AU - Srinivasan, Shankar

AU - Ricafort, Rosanna

AU - Nagarwala, Yasir

AU - Durie, Brian G M

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Background Connect MM is the first and largest observational, noninterventional, prospective registry of patients newly diagnosed with multiple myeloma (NDMM) in the United States. It collects longitudinal data on patients within clinical practice including patients in clinical trials. Patients and Methods Of the 1513 patients enrolled, 1493 were protocol-eligible. Results Median age was 67 years, 81.9% (1223/1493) were Caucasian, and 57.2% (854/1493) were male. Of these patients, 26.5% (232/877) were International Staging System stage I, 34.9% (306/877) stage II, and 38.7% (339/877) stage III. Eastern Cooperative Oncology Group performance status of 0/1/2 were reported in 96.6% (1017/1053). Clonal plasma cells > 10% were found in 91.6% (1282/1399) of patients and M-component in 98.8% (1343/1359). Hypercalcemia was present in 7.3% (108/1481) of patients, serum creatinine > 2 mg/dL in 18.3% (271/1484), anemia in 45.1% (673/1493), and bone involvement in 76.7% (1143/1490). Of the 15 National Comprehensive Cancer Network (NCCN) recommended diagnostic tests, a median of 12 were performed. Lactate dehydrogenase assessment, serum free light chain ratio, and immunofixation were reported in 38.4% (574/1493), 62.1% (927/1493), and 66% (985/1493) of patients, respectively. Quantitative immunoglobulin, β-2 microglobulin, and protein electrophoresis (serum or urine) were reported in 72.3% (1080/1493), 74.1% (1107/1493), and 78.0% (1164/1493) of patients, respectively. Bone marrow biopsy was reported in 92.2% (1376/1493), but conventional cytogenetic and fluorescence in situ hybridization analysis were reported in only 63.2% (944/1493) and 59.8% (893/1493) of patients, respectively. A high-risk cytogenetic profile (according to International Myeloma Working Group [IMWG] criteria) was found in 16.9% (253/1493). Conclusion This analysis provides insight into the demographic and disease characteristics of NDMM patients in a range of clinical practices. Creating solid records of baseline patient disease characteristics using suggested NCCN diagnostic work-up and IMWG criteria provides a foundation for monitoring disease progression and response to treatment.

AB - Background Connect MM is the first and largest observational, noninterventional, prospective registry of patients newly diagnosed with multiple myeloma (NDMM) in the United States. It collects longitudinal data on patients within clinical practice including patients in clinical trials. Patients and Methods Of the 1513 patients enrolled, 1493 were protocol-eligible. Results Median age was 67 years, 81.9% (1223/1493) were Caucasian, and 57.2% (854/1493) were male. Of these patients, 26.5% (232/877) were International Staging System stage I, 34.9% (306/877) stage II, and 38.7% (339/877) stage III. Eastern Cooperative Oncology Group performance status of 0/1/2 were reported in 96.6% (1017/1053). Clonal plasma cells > 10% were found in 91.6% (1282/1399) of patients and M-component in 98.8% (1343/1359). Hypercalcemia was present in 7.3% (108/1481) of patients, serum creatinine > 2 mg/dL in 18.3% (271/1484), anemia in 45.1% (673/1493), and bone involvement in 76.7% (1143/1490). Of the 15 National Comprehensive Cancer Network (NCCN) recommended diagnostic tests, a median of 12 were performed. Lactate dehydrogenase assessment, serum free light chain ratio, and immunofixation were reported in 38.4% (574/1493), 62.1% (927/1493), and 66% (985/1493) of patients, respectively. Quantitative immunoglobulin, β-2 microglobulin, and protein electrophoresis (serum or urine) were reported in 72.3% (1080/1493), 74.1% (1107/1493), and 78.0% (1164/1493) of patients, respectively. Bone marrow biopsy was reported in 92.2% (1376/1493), but conventional cytogenetic and fluorescence in situ hybridization analysis were reported in only 63.2% (944/1493) and 59.8% (893/1493) of patients, respectively. A high-risk cytogenetic profile (according to International Myeloma Working Group [IMWG] criteria) was found in 16.9% (253/1493). Conclusion This analysis provides insight into the demographic and disease characteristics of NDMM patients in a range of clinical practices. Creating solid records of baseline patient disease characteristics using suggested NCCN diagnostic work-up and IMWG criteria provides a foundation for monitoring disease progression and response to treatment.

KW - Baseline Disease Characteristics

KW - Diagnostics

KW - IMWG

KW - Multiple Myeloma

KW - NCCN Guidelines

UR - http://www.scopus.com/inward/record.url?scp=84931560944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931560944&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2014.12.002

DO - 10.1016/j.clml.2014.12.002

M3 - Article

VL - 15

SP - 368

EP - 376

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

IS - 6

ER -